Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ALECTINIB Cause Metastases to central nervous system? 161 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 161 reports of Metastases to central nervous system have been filed in association with ALECTINIB (ALECENSA). This represents 1.8% of all adverse event reports for ALECTINIB.

161
Reports of Metastases to central nervous system with ALECTINIB
1.8%
of all ALECTINIB reports
12
Deaths
28
Hospitalizations

How Dangerous Is Metastases to central nervous system From ALECTINIB?

Of the 161 reports, 12 (7.5%) resulted in death, 28 (17.4%) required hospitalization, and 12 (7.5%) were considered life-threatening.

Is Metastases to central nervous system Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ALECTINIB. However, 161 reports have been filed with the FAERS database.

What Other Side Effects Does ALECTINIB Cause?

Death (702) Fatigue (618) Constipation (525) Off label use (495) No adverse event (488) Disease progression (366) Rash (312) Dyspnoea (296) Drug ineffective (269) Myalgia (268)

What Other Drugs Cause Metastases to central nervous system?

TRASTUZUMAB (1,180) CAPECITABINE (663) OSIMERTINIB (560) PERTUZUMAB (540) PACLITAXEL (498) NIVOLUMAB (495) DABRAFENIB (451) CARBOPLATIN (413) DOCETAXEL (410) ADO-TRASTUZUMAB EMTANSINE (386)

Which ALECTINIB Alternatives Have Lower Metastases to central nervous system Risk?

ALECTINIB vs ALEMTUZUMAB ALECTINIB vs ALENDRONATE ALECTINIB vs ALENDRONATE\CHOLECALCIFEROL ALECTINIB vs ALENDRONIC ACID ALECTINIB vs ALEVE

Related Pages

ALECTINIB Full Profile All Metastases to central nervous system Reports All Drugs Causing Metastases to central nervous system ALECTINIB Demographics